NCT05902312Active, not recruiting
Repetitive Versus Deep Transcranial Magnetic Stimulation for Major Depression
Comparative Effectiveness of Repetitive Versus Deep Transcranial Magnetic Stimulation for Major Depression: A Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 17 Jul 2025
Brief summary (registry, in English)
The goal of this randomized controlled trial is to he effectiveness of two different TMS techniques in TRD, repetitive TMS (rTMS) and deep TMS (dTMS). The main questions it aims to answer are: type of study: clinical trial participant population/health conditions : Major Depressive Disorder To assess the superiority of dTMS over rTMS in TRD To evaluate the predictive capacity of scalable candidate biomarkers Participants will be randomly allocated to one of the two intervention groups (rTMS or dTMS).
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- First submitted
- 31 May 2023
- Start date
- 1 Jan 2024
- Primary completion date
- 1 Jan 2026
- Lead sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
- Diseases
- Depression
- NCT number
- NCT05902312
What you commit to
- Study type: Interventional
- Planned participants: 50
- From 1 Jan 2024 to the primary completion date, 1 Jan 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Having previously received TMS;
- Concomitant major unstable medical or neurological illness
- If participating in psychotherapy, must have been in stable treatment for at least three months before entry into the study, with no anticipation of change
- Currently taking more than the equivalent of 2 mg of lorazepam of a benzodiazepine daily or any dose of an anticonvulsant due to the potential to limit TMS effectiveness
Other illness
- Substance use disorder within the last three months
- Diagnosis of bipolar or psychosis spectrum disorder
- Anxiety or personality disorder that is assessed by a study investigator to be the primary cause and causing greater impairment than MDD
- Intracranial implant, cardiac pacemaker or implanted medication pump
Lab values
- Significant laboratory abnormality;
Other
- Active suicidal intent
- Pregnancy
Who the study is looking for
- Diagnosis of Major Depressive Disorder, at least moderate intensity, single or recurrent episode
- HRSD-17 score of at least 18
- No improvement to at least two adequate courses of antidepressants (based on the ATHF) or were unable to tolerate at least two separate trials of antidepressants of inadequate dose and duration
- On a stable antidepressant regimen for the past four weeks before screening
- Patients with a chronic depressive episode \>2 years and who have previously received ECT or ketamine will be eligible to participate
Age in the registry: 21 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHUM Coordinator of this site? Confirm its status | Montreal | Canada | Unknown status |
Related publications
- Pilot randomized trial of intermittent theta-burst stimulation versus H-Coil transcranial magnetic stimulation for treatment-resistant depression.Psychiatry Res · 2026 · PMID 42302659
This page is information, not medical advice. Discuss any trial with your doctor.